Your browser doesn't support javascript.
The State of Melanoma: Emergent Challenges and Opportunities.
Atkins, Michael B; Curiel-Lewandrowski, Clara; Fisher, David E; Swetter, Susan M; Tsao, Hensin; Aguirre-Ghiso, Julio A; Soengas, Maria S; Weeraratna, Ashani T; Flaherty, Keith T; Herlyn, Meenhard; Sosman, Jeffrey A; Tawbi, Hussein A; Pavlick, Anna C; Cassidy, Pamela B; Chandra, Sunandana; Chapman, Paul B; Daud, Adil; Eroglu, Zeynep; Ferris, Laura K; Fox, Bernard A; Gershenwald, Jeffrey E; Gibney, Geoffrey T; Grossman, Douglas; Hanks, Brent A; Hanniford, Douglas; Hernando, Eva; Jeter, Joanne M; Johnson, Douglas B; Khleif, Samir N; Kirkwood, John M; Leachman, Sancy A; Mays, Darren; Nelson, Kelly C; Sondak, Vernon K; Sullivan, Ryan J; Merlino, Glenn.
  • Atkins MB; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C. gmerlino@helix.nih.gov Mba41@georgetown.edu.
  • Curiel-Lewandrowski C; Department of Dermatology, The University of Arizona Cancer Center Skin Cancer Institute, College of Medicine, University of Arizona, Tucson, Arizona.
  • Fisher DE; Department of Dermatology & Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Swetter SM; Department of Dermatology, Pigmented Lesion & Melanoma Program, Stanford University Medical Center & Cancer Institute, VA Palo Alto Health Care System, Palo Alto, California.
  • Tsao H; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Aguirre-Ghiso JA; Division of Hematology & Oncology, Departments of Medicine, Otolaryngology, & Oncological Sciences, Precision Immunology Institute, Black Family Stem Cell Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Soengas MS; Molecular Oncology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
  • Weeraratna AT; Department of Biochemistry & Molecular Biology, Johns Hopkins Bloomberg School of Public Health & Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Flaherty KT; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Herlyn M; The Wistar Institute, Philadelphia, Pennsylvania.
  • Sosman JA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
  • Tawbi HA; Division of Cancer Medicine, Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Pavlick AC; Weill Cornell Medical College, New York, New York.
  • Cassidy PB; Knight Cancer Institute & Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
  • Chandra S; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
  • Chapman PB; Memorial Sloan Kettering Cancer Center & Weill Cornell Medical College, New York, New York.
  • Daud A; University of California, San Francisco, California.
  • Eroglu Z; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Ferris LK; Department of Dermatology, University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Fox BA; Department of Molecular Microbiology & Immunology, Oregon Health & Science University, Laboratory of Molecular & Tumor Immunology, Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon.
  • Gershenwald JE; Departments of Surgical Oncology & Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Gibney GT; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, D.C.
  • Grossman D; Huntsman Cancer Institute & Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, Utah.
  • Hanks BA; Division of Medical Oncology, Department of Medicine, Department of Pharmacology & Cancer Biology, Center for Cancer Immunotherapy, Duke University Medical Center, Durham, North Carolina.
  • Hanniford D; Department of Pathology, NYU Grossman School of Medicine, Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer Center, New York, New York.
  • Hernando E; Department of Pathology, NYU Grossman School of Medicine, Interdisciplinary Melanoma Cooperative Group, Perlmutter Cancer Center, New York, New York.
  • Jeter JM; Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, Utah.
  • Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Khleif SN; The Loop Laboratory for Immuno-Oncology Lombardi Cancer Center, Georgetown School of Medicine, Georgetown University, Washington, D.C.
  • Kirkwood JM; University of Pittsburgh, Pittsburgh, Pennsylvania.
  • Leachman SA; Knight Cancer Institute & Department of Dermatology, Oregon Health & Science University, Portland, Oregon.
  • Mays D; Department of Internal Medicine, College of Medicine, The Ohio State University, Center for Tobacco Research, The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio.
  • Nelson KC; Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Clin Cancer Res ; 27(10): 2678-2697, 2021 05 15.
Article in English | MEDLINE | ID: covidwho-1015729
ABSTRACT
Five years ago, the Melanoma Research Foundation (MRF) conducted an assessment of the challenges and opportunities facing the melanoma research community and patients with melanoma. Since then, remarkable progress has been made on both the basic and clinical research fronts. However, the incidence, recurrence, and death rates for melanoma remain unacceptably high and significant challenges remain. Hence, the MRF Scientific Advisory Council and Breakthrough Consortium, a group that includes clinicians and scientists, reconvened to facilitate intensive discussions on thematic areas essential to melanoma researchers and patients alike, prevention, detection, diagnosis, metastatic dormancy and progression, response and resistance to targeted and immune-based therapy, and the clinical consequences of COVID-19 for patients with melanoma and providers. These extensive discussions helped to crystalize our understanding of the challenges and opportunities facing the broader melanoma community today. In this report, we discuss the progress made since the last MRF assessment, comment on what remains to be overcome, and offer recommendations for the best path forward.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Practice Guidelines as Topic / SARS-CoV-2 / COVID-19 / Medical Oncology / Melanoma Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research Limits: Humans Language: English Journal: Clin Cancer Res Journal subject: Neoplasms Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Skin Neoplasms / Practice Guidelines as Topic / SARS-CoV-2 / COVID-19 / Medical Oncology / Melanoma Type of study: Diagnostic study / Observational study / Prognostic study / Qualitative research Limits: Humans Language: English Journal: Clin Cancer Res Journal subject: Neoplasms Year: 2021 Document Type: Article